Novartis new data on safety and efficacy of Zolgensma in older and heavier children with SMA

 

• The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies 1-6
  

• Nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy 1-6

• The SMART study is the first open-label clinical study of Zolgensma to include previously treated patients

https://finance.yahoo.com/news/novartis-presents-data-safety-efficacy-061500660.html